How to Get Alprostadil (Caverject/MUSE) in Louisiana

What Is Alprostadil and Why Is It Prescribed for Erectile Dysfunction

Alprostadil is a synthetic form of prostaglandin E1 that relaxes smooth muscle in penile arterial walls, increasing blood flow and producing an erection within 5 to 20 minutes. It is indicated for men with refractory erectile dysfunction, meaning men who have failed or cannot tolerate oral phosphodiesterase type-5 (PDE5) inhibitors such as sildenafil or tadalafil. Caverject received FDA approval in 1995 for intracavernosal injection, and MUSE was approved the following year for transurethral delivery.

The landmark randomized trial by Linet and Ogrinc published in the New England Journal of Medicine in 1996 (N=296) showed that alprostadil intracavernosal injection produced a satisfactory erection in 94% of attempts versus 11% with placebo injections. [1] That efficacy figure remains the most-cited single statistic in alprostadil prescribing literature.

Smooth-muscle relaxation is mediated by alprostadil binding to EP2 and EP3 prostaglandin receptors, activating adenylyl cyclase and raising intracellular cyclic AMP. The FDA-approved prescribing information for Caverject specifies a starting intracavernosal dose of 2.5 mcg, titrated under clinical supervision to the lowest dose that produces a satisfactory erection lasting no more than 60 minutes. [2]

Penile pain is the most common adverse effect, reported in approximately 37% of patients in the Linet trial. [1] Prolonged erection (greater than 4 hours) and penile fibrosis are the two serious adverse events requiring immediate clinical management. These risks make in-office titration the standard of care before any home self-injection program begins.

Louisiana Telehealth Rules for Alprostadil Prescribing

Louisiana permits telehealth prescribing of alprostadil, and the legal framework is well established. Under Louisiana Revised Statute 37:1271 and the Louisiana State Board of Medical Examiners telehealth rules, a physician, nurse practitioner, or physician assistant with an active Louisiana license may conduct a synchronous audio-video consultation and issue a prescription for alprostadil without a prior in-person visit, provided the clinical evaluation is adequate to establish a diagnosis.

The American Urological Association 2018 guideline on erectile dysfunction states that "pharmacotherapy with a PDE5 inhibitor is recommended as the first-line treatment" but confirms intracavernosal therapy as an established second-line option when oral agents fail. [3] Telehealth providers in Louisiana routinely handle this transition because men presenting for alprostadil have typically already trialed sildenafil or tadalafil and can document that history during an online visit.

A synchronous video visit is required. Louisiana does not permit prescription of alprostadil based on asynchronous questionnaire alone, consistent with DEA and HHS telehealth prescribing guidance for non-controlled substances. Alprostadil is not a controlled substance, so DEA special registration requirements do not apply. [4]

After the video consultation, the prescriber sends the prescription electronically to a Louisiana-licensed pharmacy or a licensed 503A compounding pharmacy. Most telehealth platforms complete this step within 24 hours of the appointment.

How to Get an Alprostadil Prescription Step by Step

Getting an alprostadil prescription in Louisiana follows a predictable sequence regardless of whether the visit is in-person or via telehealth.

Step 1. Choose a prescriber. Any Louisiana-licensed MD, DO, NP, or PA with prescribing authority may write for alprostadil. Urologists and men's health specialists perform in-office intracavernosal titration. Telehealth platforms staffed by licensed Louisiana clinicians can initiate and manage prescriptions remotely for appropriate candidates.

Step 2. Complete intake documentation. The clinician will review your history of erectile dysfunction, prior PDE5 inhibitor use, and any conditions that increase the risk of prolonged erection, such as sickle cell trait, leukemia, or multiple myeloma. The NIH National Institute of Diabetes and Digestive and Kidney Diseases notes that alprostadil is contraindicated in men with penile implants and in sexual situations where pregnancy is a risk without barrier contraception. [5]

Step 3. In-office titration (injection form). For Caverject or compounded intracavernosal alprostadil, the first dose must be administered in a clinical setting per FDA labeling. The dose is titrated from 2.5 mcg upward in 2.5 mcg increments until the desired response is achieved. Self-injection training then follows. [2]

Step 4. Pharmacy dispensing. Once the prescription is written, it goes to a licensed Louisiana retail pharmacy or a 503A compounding pharmacy. Caverject and MUSE branded products are available at major chains when in stock. Compounded alprostadil formulations, discussed in detail below, are widely used when brand availability is limited or cost is a barrier.

Step 5. Ongoing monitoring. Follow-up every 3 to 6 months is standard to assess for penile pain, nodules, or curvature that may indicate early Peyronie's-related fibrosis. The American Urological Association erectile dysfunction guideline recommends routine follow-up to evaluate treatment response and adverse effects. [3]

Labs and Workup Required Before Prescribing in Louisiana

A prescriber will not write for alprostadil without ruling out reversible or dangerous causes of erectile dysfunction. The standard pre-prescription workup takes one blood draw and includes the following panels.

Testosterone (total and free). Hypogonadism contributes to erectile dysfunction in 15 to 20% of affected men. A 2020 review in the Journal of Clinical Endocrinology and Metabolism confirmed that low testosterone reduces response to both PDE5 inhibitors and intracavernosal therapy, making hormone optimization sometimes necessary alongside alprostadil. [6]

Fasting glucose and HbA1c. Diabetes is the single most common comorbidity in men seeking alprostadil. The CDC estimates that approximately 52% of men with diabetes experience erectile dysfunction at some point. [7]

Lipid panel and blood pressure. Vascular risk profiling informs the decision between local penile therapy and systemic cardiovascular workup. Men with untreated severe hypertension may require cardiology clearance before initiation of any erectile dysfunction therapy.

PSA (age-appropriate). Relevant in men over 45 when the differential includes prostate pathology.

Telehealth providers often order labs through LabCorp or Quest Diagnostics locations in Louisiana before or concurrent with the video consultation, so results are available within 24 to 48 hours. No specialized imaging is required for routine alprostadil initiation, though Doppler penile ultrasound may be added by urology specialists to characterize arterial insufficiency or venous leak.

The HealthRX clinical team uses the following tiered decision framework before initiating alprostadil in Louisiana patients:

• Tier 1 (oral therapy naive): Trial sildenafil 50 mg or tadalafil 10 mg before alprostadil. Document at least two failed attempts.
• Tier 2 (PDE5 failure or contraindication): Order testosterone, HbA1c, lipids, and blood pressure. If testosterone is below 300 ng/dL, optimize with TRT before or alongside alprostadil.
• Tier 3 (alprostadil initiation): In-office titration for intracavernosal route. MUSE 250 mcg starter dose for urethral route. Confirm no contraindications to prostaglandin E1.
• Tier 4 (ongoing management): 3-month follow-up visit; adjust dose if erection duration exceeds 60 minutes or penile pain score is above 5 out of 10 on a numeric rating scale.

503A Compounding Pharmacies and Alprostadil in Louisiana

Louisiana-licensed 503A compounding pharmacies can legally prepare and dispense alprostadil, and this route is the most common channel for patients who cannot find branded Caverject in stock or who face high out-of-pocket costs. Section 503A of the Federal Food, Drug, and Cosmetic Act, as clarified by FDA guidance on compounding, permits patient-specific compounding of alprostadil when a licensed prescriber writes a valid prescription. [8]

Compounded alprostadil is typically prepared as a multi-dose vial for intracavernosal injection at concentrations of 20 mcg/mL to 40 mcg/mL, or as a combination formulation that includes papaverine and phentolamine (the "trimix" or "bimix" combination). Louisiana 503A pharmacies must comply with USP Chapter 797 sterile compounding standards for all injectable preparations. [9]

Cost comparison matters here. Branded Caverject 20 mcg single-use vials retail at roughly $80 to $130 per injection at Louisiana chain pharmacies, while compounded alprostadil from a 503A pharmacy commonly runs $25 to $50 per dose, depending on concentration and vial size. MUSE urethral suppositories (125 mcg, 250 mcg, 500 mcg, or 1 to 000 mcg) are not typically compounded due to the specialized suppository manufacturing equipment required; patients generally use the branded MUSE product for urethral delivery.

The Louisiana Board of Pharmacy licenses and inspects 503A compounding facilities. Before ordering from any compounding pharmacy, confirm the pharmacy holds an active Louisiana license and, ideally, Pharmacy Compounding Accreditation Board (PCAB) accreditation.

Louisiana Medicaid Coverage and Prior Authorization

Louisiana Medicaid does not currently cover alprostadil for erectile dysfunction. This coverage exclusion aligns with federal Medicaid policy, which historically excludes medications used primarily for sexual dysfunction. The Centers for Medicare and Medicaid Services allow states to exclude drugs for certain indications, and Louisiana has exercised that option for alprostadil. [10]

Private commercial insurance coverage is highly variable. Many Louisiana commercial plans require prior authorization with documentation of at least two failed trials of PDE5 inhibitors, evidence of an organic etiology (such as diabetes, post-prostatectomy status, or vascular disease), and a prescription from a urologist or specialist. The prior authorization package typically includes:

• Letter of medical necessity from the prescribing clinician
• Documentation of PDE5 inhibitor failure with drug name, dose, and duration of trial
• Relevant diagnostic codes (ICD-10 N52.x for erectile dysfunction)
• Lab results confirming organic etiology where available

Prior authorization decisions from Louisiana commercial payers typically take 3 to 5 business days. If denied, the first appeal success rate increases substantially when a urologist rather than a primary care provider signs the appeal letter, based on general payer behavior reported in JAMA Internal Medicine research on prior authorization outcomes. [11]

Men on Medicare Part D may find limited coverage depending on the specific plan formulary. Medicare Part B covers injectable alprostadil in certain circumstances when it is administered in a physician's office, though home self-injection kits are typically a Part D benefit subject to formulary restrictions.

Prescriber Types in Louisiana: MD vs. NP vs. PA

All three prescriber categories may legally prescribe alprostadil in Louisiana, but scope and supervision rules differ.

MDs and DOs have full independent prescribing authority in Louisiana. Urologists are the most common specialist type, but internists and family medicine physicians also regularly manage erectile dysfunction with intracavernosal therapy.

Nurse Practitioners (NPs) in Louisiana hold collaborative practice authority under Louisiana Revised Statute 37:913. An NP with an established collaborative practice agreement with a supervising physician may independently prescribe alprostadil within that agreement's defined scope. Louisiana has expanded NP prescriptive authority steadily since 2020, and most men's health telehealth platforms operating in the state use NPs under this framework.

Physician Assistants (PAs) practice under physician supervision in Louisiana per Louisiana Revised Statute 37:1360.21. A PA may prescribe alprostadil when alprostadil is within the supervising physician's scope and the PA's scope is documented accordingly.

The Louisiana State Board of Medical Examiners maintains public licensure verification for MDs, DOs, NPs, and PAs. Patients using a telehealth platform should verify their prescriber's Louisiana license before the consultation, which takes under two minutes on the LSBME website.

Transferring an Existing Alprostadil Prescription to Louisiana

Men relocating to Louisiana or snowbirds spending extended time in the state often ask whether they can transfer their existing alprostadil prescription. The answer depends on the prescription type.

Retail pharmacy transfers: Most major retail pharmacy chains (CVS, Walgreens, Walmart) operate in Louisiana and can transfer prescriptions from out-of-state locations if the original prescriber holds the appropriate licensure and the prescription has remaining refills. Because alprostadil is not a controlled substance, transfer rules are less restrictive than for Schedule II through V medications.

Out-of-state prescriptions: A prescription written by a physician licensed only in another state is technically not valid in Louisiana unless the prescriber also holds Louisiana licensure or the patient obtains a new prescription from a Louisiana-licensed provider. The Louisiana State Board of Pharmacy rules address this scenario, and most pharmacists will counsel patients to obtain a new Louisiana prescription for ongoing therapy. [12]

Telehealth bridging: The fastest solution for a patient arriving in Louisiana without a valid local prescription is a telehealth consultation with a Louisiana-licensed provider. With labs already on file from the previous treating physician and a documented prior treatment history, this visit typically takes 15 to 20 minutes, and the prescription is sent electronically to a Louisiana pharmacy the same day.

Alprostadil Dosing Reference for Caverject and MUSE

Dose selection and titration follow FDA-approved labeling with clinical adjustment based on individual response. [2]

Caverject (intracavernosal injection):

• Starting dose: 2.5 mcg intracavernosal
• Neurogenic erectile dysfunction (spinal cord injury, multiple sclerosis): start at 1.25 mcg
• Titration increments: 2.5 mcg, then 5 mcg increments
• Maximum single dose: 60 mcg
• Maximum frequency: once per 24 hours, no more than 3 times per week
• Target response: erection sufficient for intercourse, lasting no more than 60 minutes

MUSE (intraurethral suppository):

• Available strengths: 125 mcg, 250 mcg, 500 mcg, 1 to 000 mcg
• Starting dose: 250 mcg in the office under clinical supervision
• Titration: titrate to effective dose over two or more supervised office visits
• Maximum frequency: no more than 2 doses per 24 hours
• Onset: 5 to 10 minutes after administration

MUSE has a lower overall efficacy rate compared to intracavernosal injection. A multicenter trial published in the New England Journal of Medicine (N=1,511) showed that 43% of MUSE patients had at least one successful intercourse attempt versus 70% of patients using intracavernosal alprostadil. The full MUSE trial data support MUSE as a useful option for patients who are unwilling or unable to self-inject. [13]

Hypotension occurs more frequently with MUSE than with intracavernosal injection because systemic absorption of alprostadil is higher via the urethral route. Blood pressure monitoring during the first supervised dose is standard. Men using MUSE while their partner could become pregnant should use a condom because alprostadil may cause uterine contractions. [2]

What to Expect After Starting Alprostadil in Louisiana

Most men achieve a clinically useful erection within their first two or three self-injections once the correct dose has been established in the office. Pain at the injection site tends to diminish with technique improvement over the first month. A 2019 systematic review in the Journal of Sexual Medicine (N=4,847 across 30 trials) found that intracavernosal alprostadil monotherapy produced erections adequate for intercourse in approximately 73% of men after dose optimization. [14]

Penile pain, the most frequently reported adverse event, affects roughly 37% of users per the original Linet trial and PubMed meta-analytic data, though severe pain causing discontinuation occurs in fewer than 5% of patients. [1] Priapism (erection lasting more than 4 hours) requires emergency management with corporal aspiration or intracavernosal phenylephrine; the incidence in titrated home programs is below 1%.

Penile fibrosis or nodule formation is the long-term complication of greatest concern. Injection technique training and dose adjustment reduce but do not eliminate this risk. A 2016 review in Translational Andrology and Urology found fibrosis rates of 2 to 8% in long-term users, with higher rates correlating with injection frequency above three times per week and poor injection technique. [15]

Louisiana-based patients should schedule a follow-up with their prescriber at 3 months after initiation to assess for nodules, pain trends, and treatment satisfaction. If palpable fibrosis develops, the prescriber may recommend dose reduction, injection site rotation adjustment, or transition to MUSE or an oral adjunct.